Analystreport

Mirati Therapeutics Inc (NASDAQ: MRTX) had its "buy" rating re-affirmed by analysts at Cann. They now have a $62.00 price target on the stock.

Mirati Therapeutics, Inc.  (MRTX) 
Last mirati therapeutics, inc. earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.mirati.com/node/5806